Edition:
United Kingdom

Cellectar Biosciences Inc (CLRB.OQ)

CLRB.OQ on NASDAQ Stock Exchange Capital Market

2.70USD
21 Sep 2018
Change (% chg)

$-0.06 (-2.17%)
Prev Close
$2.76
Open
$2.76
Day's High
$2.79
Day's Low
$2.63
Volume
24,127
Avg. Vol
34,406
52-wk High
$20.40
52-wk Low
$2.03

Chart for

About

Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery... (more)

Overall

Beta: 1.02
Market Cap(Mil.): $23.88
Shares Outstanding(Mil.): 13.92
Dividend: --
Yield (%): --

Financials

  CLRB.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -1.24 -- --
ROI: -103.68 15.07 14.61
ROE: -105.20 16.59 16.33

BRIEF-Cellectar Granted Orphan Drug Designation For CLR 131

* CELLECTAR GRANTED ORPHAN DRUG DESIGNATION FOR CLR 131 TO TREAT RHABDOMYOSARCOMA Source text for Eikon: Further company coverage:

09 May 2018

BRIEF-Cellectar Biosciences Appoints Brian M. Posner As Chief Financial Officer

* CELLECTAR BIOSCIENCES APPOINTS BRIAN M. POSNER AS CHIEF FINANCIAL OFFICER

04 Apr 2018

BRIEF-Cellectar Granted Seminal U.S. Patent For Phospholipid-Ether Analogs As Cancer-Targeting Drug Vehicles

* CELLECTAR GRANTED SEMINAL U.S. PATENT FOR PHOSPHOLIPID-ETHER ANALOGS AS CANCER-TARGETING DRUG VEHICLES Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

27 Mar 2018

Competitors

Earnings vs. Estimates